Your browser doesn't support javascript.

Biblioteca Virtual em Saúde

Brasil

Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:

Exportar

Email
Adicionar mais destinatários
| |

Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study.

Elmariah, Sammy; McCarthy, Cian; Ibrahim, Nasrien; Furman, Deborah; Mukai, Renata; Magaret, Craig; Rhyne, Rhonda; Barnes, Grady; van Kimmenade, Roland R J; Januzzi, James L.
Open Heart; 5(2): e000916, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30487984

OBJECTIVE:

Severe aortic valve stenosis (AS) develops via insidious processes and can be challenging to correctly diagnose. We sought to develop a circulating biomarker panel to identify patients with severe AS.

METHODS:

We enrolled study participants undergoing coronary or peripheral angiography for a variety of cardiovascular diseases at a single academic medical centre. A panel of 109 proteins were measured in blood obtained at the time of the procedure. Statistical learning methods were used to identify biomarkers and clinical parameters that associate with severe AS. A diagnostic model incorporating clinical and biomarker results was developed and evaluated using Monte Carlo cross-validation.

RESULTS:

Of 1244 subjects (age 66.4±11.5 years, 28.7% female), 80 (6.4%) had severe AS (defined as aortic valve area (AVA) <1.0 cm2). A final model included age, N-terminal pro-B-type natriuretic peptide, von Willebrand factor and fetuin-A. The model had good discrimination for severe AS (OR=5.9, 95% CI 3.5 to 10.1, p<0.001) with an area under the curve of 0.76 insample and 0.74 with cross-validation. A diagnostic score was generated. Higher prevalence of severe AS was noted in those with higher scores, such that 1.6% of those with a score of 1 had severe AS compared with 15.3% with a score of 5 (p<0.001), and score values were inversely correlated with AVA (r=-0.35; p<0.001). At optimal model cut-off, we found 76% sensitivity, 65% specificity, 13% positive predictive value and 98% negative predictive value.

CONCLUSIONS:

We describe a novel, multiple biomarker approach for diagnostic evaluation of severe AS.Trial registration number: NCT00842868.
Selo DaSilva